Anti-obesity medications slash heart disease risk in obese patients, study finds

By Dr. Liji Thomas, MDMay 15 2024Reviewed by Benedette Cuffari, M.Sc. Obesity is a major cause of illness and death, mainly due to cardiovascular disease , which claims about 18 million deaths each year. New anti-obesity medications are now being used both experimentally and clinically to manage this growing threat to public health .

What are AOMs? Although AOMs have been approved to manage obesity, the current study used real-world data to evaluate their effects on different cardiovascular conditions. Tirzepatide was approved in 2022 and subsequently investigated for its impact on weight loss. To this end, tirzepatide has been shown to induce up to 20% weight loss, which led to its approval in 2023 for this indication.

While the average age was slightly lower in the AOM cohort, this cohort had a higher comorbidity score of two or more and was more likely to have a low socioeconomic status . The AOM cohort also had a higher prevalence of hypertension, 72%, as compared to 61% among controls, as well as type 2 diabetes and hyperlipidemia, at about 65% and 40%, respectively, as compared to 25% and 30%, respectively.

Females were at a 26% reduced risk of CVD than males, whereas residents from low and medium SES areas were at a higher risk than those from high SES areas. The incidence of heart failure was 4.9% as compared to 6.1% in untreated patients. Similarly, atrial fibrillation occurred in 3.8% of AOM recipients as compared to 5.1% of untreated patients.

Source: Healthcare Press (healthcarepress.net)

Blood Cardiovascular Disease Diabetes Drugs GLP-1 Glucagon Glucose Heart Heart Failure Hyperlipidemia Medicare Obesity Public Health Semaglutide Type 2 Diabetes

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Anti-obesity jab ‘cuts risk of heart attack or stroke regardless of weight lost’A weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% compared with those given a placebo.
Source: itvnews - 🏆 69. / 61 Read more »

Trial reveals anti-inflammatory power of aerobic exercise in adults with obesityNew research presented at this year's European Congress on Obesity (ECO) in Venice, Italy (12–15 May), reveals the anti-inflammatory power of moderate-to-vigorous aerobic exercise in adults living with the low-grade inflammation of obesity, shedding light on its potential to help prevent multiple metabolic diseases including type 2 diabetes...
Source: medical_xpress - 🏆 101. / 51 Read more »

Gradual weaning off anti-obesity jabs could help avoid weight gainResearchers found a lower dose of the drug semaglutide could also be effective for weight loss when combined with lifestyle changes.
Source: Glasgow_Times - 🏆 76. / 59 Read more »

Gradual weaning off anti-obesity jabs could help avoid weight gainResearchers found a lower dose of the drug semaglutide could also be effective for weight loss when combined with lifestyle changes.
Source: Observer_Owl - 🏆 18. / 72 Read more »

Social determinants of health tied to atherosclerotic CVD riskBoth individual- and area-level social determinants of health (SDOH) are associated with atherosclerotic cardiovascular disease (ASCVD) risk, according to a study published in JAMA Network Open.
Source: medical_xpress - 🏆 101. / 51 Read more »

Fat-enlarged axillary nodes on mammogram may indicate higher CVD riskFat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual meeting of the American Roentgen Ray Society, held May 5–9 in Boston.
Source: medical_xpress - 🏆 101. / 51 Read more »